Search results for "TUMORS"

showing 10 items of 1138 documents

How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a propensity-matched study

2020

Background: Recently, it was reported that minimally invasive surgery (MIS) has a negative impact on early-stage cervical cancer (ECC) patient survival. At the same time, advantages of MIS regarding quality of life and low rate of intra- and postoperative complications are well known. Therefore, it is essential to select patients who may benefit from MIS without worsening their oncologic outcomes. The aim of this study is to investigate which pathological factors could guide surgeons’ choice about the best approach in ECC. Patients and Methods: Patients with 2009 FIGO stage from IA1 with lymphovascular space invasion (LVSI) to IB1/IIA1 treated by open or laparoscopic surgery were judged eli…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentlaparoscopyUterine Cervical NeoplasmsHysterectomyDisease-Free Survivalopen surgeryYoung Adult03 medical and health sciences0302 clinical medicineSurgical oncologymedicineHumansMinimally Invasive Surgical ProceduresRadical HysterectomyPropensity ScoreLaparoscopyGrading (tumors)minimally invasive surgeryAgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancermedicine.diagnostic_testbusiness.industryParametrialCervical cancer; laparoscopy; minimally invasive surgery; open surgery; radical hysterectomy; tumor diameterHazard ratioMiddle Agedmedicine.diseaseSurgerySurvival RateTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncology030220 oncology & carcinogenesisradical hysterectomyCervical cancerFemale030211 gastroenterology & hepatologySurgerytumor diameterbusiness
researchProduct

Dermoscopy of cutaneous smooth muscle neoplasms: a morphological study of 136 cases

2019

BACKGROUND: A variety of cutaneous smooth muscle neoplasms may arise in the skin and are frequently unrecognized by clinicians. There is sparse data relating to the dermoscopy of piloleiomyomas (PL), and nothing has been published about the dermoscopy of angioleiomyomas (AL) and leiomyosarcomas (LS). OBJECTIVES: To evaluate the morphological findings of a large series of cutaneous PL, AL and LS under dermoscopic observation, comparing these findings among them. METHODS: Digital dermoscopic images of 136 histopathologically confirmed cases of cutaneous smooth muscle neoplasms (114 PL, 13 AL and 9 LS) collected from 10 Hospitals in Spain, Austria and Italy were evaluated for the presence of d…

AdultLeiomyosarcomaMaleLeiomyosarcomaPathologymedicine.medical_specialtySkin NeoplasmsAngiomyomaDermoscopyDermoscopy angioleiomyoma leiomyosarcoma piloleiomyoma smooth muscle tumorsDiagnostic accuracyDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSmooth musclemedicineHumansAgedDermoscopy; angioleiomyoma; leiomyosarcoma ; piloleiomyoma; smooth muscle tumorssmooth muscle tumorsbusiness.industryLarge seriesMuscle SmoothleiomyosarcomaMiddle Agedangioleiomyomamedicine.diseaseAngiomyomaInfectious Diseases030220 oncology & carcinogenesisMuscleFemaleSmoothpiloleiomyomaAdult; Aged; Angiomyoma; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Muscle Smooth; Skin Neoplasms; DermoscopybusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Early Lung Function Abnormalities in Acromegaly.

2014

BACKGROUND: Acromegaly is an insidious disorder caused by a pituitary growth hormone (GH)-secreting adenoma resulting in high circulating levels of GH and insulin-like growth factor I (IGF-I). Respiratory disorders are common complications in acromegaly, and can severely impact on quality of life, eventually affecting mortality. OBJECTIVES: The present study aimed to explore structural and functional lung alterations of acromegalic subjects. METHODS: We enrolled 10 consecutive patients (M/F: 5/5) affected by acromegaly. In all patients, magnetic resonance imaging (MRI) revealed the presence of pituitary tumor. All patients underwent clinical, lung functional, biological, and radiological as…

AdultLung DiseasesMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTime FactorsAdenomaVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyspirometry dyspnea acromegalySettore MED/13 - EndocrinologiaPredictive Value of TestsDLCOForced Expiratory VolumeDiffusing capacityInternal medicineAcromegalymedicineHumansLung volumesRespiratory systemLungAgedLungbusiness.industryPituitary tumorsMiddle Agedrespiratory systemmedicine.diseaseMagnetic Resonance Imagingrespiratory tract diseasesRadiographyEarly Diagnosismedicine.anatomical_structureCase-Control StudiesPulmonary Diffusing CapacityFemaleGrowth Hormone-Secreting Pituitary AdenomaLung Volume Measurementsbusiness
researchProduct

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II …

2019

Abstract Background Hepatic arterial embolisation therapy (HAET) is a treatment of liver metastases of gastrointestinal neuroendocrine tumours (GI-NETs). HAET increases circulating vascular endothelial growth factor levels. Everolimus is a treatment in NETs that may have antiangiogenic activity. Methods This phase II study was conducted in patients with predominant and progressive liver metastases from GI-NETs. Everolimus was initiated 7–30 days after HAET. The hypothesis was that everolimus after HAET would increase hepatic progression-free survival (hPFS) rate at 24 months from 35% to 50%. Results Among the 74 patients included, 88% had small-bowel primary tumour, 43% had grade I and 57% …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyLung NeoplasmsPhases of clinical researchAntineoplastic AgentsBone NeoplasmsGastroenterologyStreptozocin03 medical and health scienceschemistry.chemical_compoundHepatic Artery0302 clinical medicineInternal medicineMucositisHumansMedicineIn patientEverolimusChemoembolization TherapeuticTrial registrationPeritoneal NeoplasmsAgedGastrointestinal NeoplasmsAged 80 and overGastrointestinal tractAntibiotics AntineoplasticEverolimusbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseEmbolization TherapeuticProgression-Free SurvivalConfidence intervalVascular endothelial growth factorNeuroendocrine Tumors030104 developmental biologyOncologychemistryDoxorubicin030220 oncology & carcinogenesisFemaleLymph Nodesbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer

2021

Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A conventional 3 + 3 dose finding design was used. FTD/TPI was administered on days 1–5 and 8–12 of a 28-day cycle, REG on days 2–22. Two dose levels were used: FTD/TPI 25 mg/m2 b.i.d. + REG 120 mg/d, then escalated to FTD/TPI 35 mg/m2 b.i.d. + REG 120 mg/d. Results: In total, 12 patients were treated at two dose levels. Three dose-limiting toxicities were observed; all were grade 3 hypertension causally attributed to REG. Recommended Phase II dose …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPyrrolidinesMaximum Tolerated DosePyridinesColorectal cancerAdministration OralTrifluridineDrug Administration ScheduleTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryRegorafenibInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineDose escalationHumansResponse Evaluation Criteria in Solid TumorsAgedTipiracilDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsGeneral MedicineMiddle Agedmedicine.diseaseProgression-Free SurvivalDrug Combinations030104 developmental biologyOncologychemistryThird lineDrug Resistance Neoplasm030220 oncology & carcinogenesisHypertensionToxicityFeasibility StudiesFemaleColorectal NeoplasmsbusinessThyminemedicine.drugFuture Oncology
researchProduct

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct

Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster

2016

Contains fulltext : 172720.pdf (Publisher’s version ) (Open Access) Recently, activating mutations of the hypoxia-inducible factor 2alpha gene (HIF2A/EPAS1) have been recognized to predispose to multiple paragangliomas (PGLs) and duodenal somatostatinomas associated with polycythemia, and ocular abnormalities. Previously, mutations in the SDHA/B/C/D, SDHAF2, VHL, FH, PHD1, and PHD2 genes have been associated with HIF activation and the development of pseudohypoxic (cluster-1) PGLs. These tumors overlap in terms of tumor location, syndromic presentation, and noradrenergic phenotype to a certain extent. However, they also differ especially by clinical outcome and by presence of other tumors o…

AdultMale0301 basic medicineOriginal articleCancer ResearchAdolescentMicroarraySDHBSDHABiologylcsh:RC254-282Oxidative PhosphorylationParagangliomaYoung Adult03 medical and health sciences0302 clinical medicineParagangliomaBasic Helix-Loop-Helix Transcription FactorsmedicineJournal ArticleCluster AnalysisHumansChildHypoxiaAgedGeneticsGene Expression ProfilingVascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeGene Expression Regulation NeoplasticGene expression profiling030104 developmental biologyHypoxia-inducible factors030220 oncology & carcinogenesisMutationFemaleSDHDTranscriptomeProtein BindingNeoplasia
researchProduct